The global pharmaceutical intermediates market is set for significant expansion, with revenue expected to grow from USD 36,620.2 million in 2025 to USD 57,031.9 million by 2035, at a steady CAGR of 4.5%. In 2024, the market is valued at USD 35,081.4 million, highlighting the sector's accelerating momentum.

MRTX-1133 is one of the first potent, selective KRAS G12D inhibitors that binds noncovalently to the S-IIP of the active and inactive states of KRAS G12D [33]. Preclinical studies showed significant efficacy, with tumor regression in xenograft mouse models occurring in a dose-dependent manner [34].

Signal transducer and activator of transcription 5 (STAT5) is an attractive therapeutic target, but successful targeting of STAT5 has proved to be difficult. Here we report the development of AK-2292 as a first, potent and selective small-molecule degrader of both STAT5A and STAT5B isoforms.